Stocktoria
Shattuck Labs, Inc. STTK
Nasdaq · stock · Pharmaceutical Preparations · website · IPO 2020-10-09
Shattuck Labs, Inc. financials (annual)
Bars are annual figures from 2019 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue | $1.0M | $5.7M | $1.7M | $652,000 | $30.0M | $9.9M | $9.9M |
| R&D expense | $35.3M | $67.2M | $74.3M | $82.9M | $56.6M | $37.5M | $29.2M |
| Operating income | -$51.5M | -$80.6M | -$92.0M | -$103.3M | -$45.3M | -$36.9M | -$25.1M |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net income | -$48.8M | -$75.4M | -$87.3M | -$101.9M | -$45.0M | -$36.6M | -$24.0M |
| EPS (diluted) | $-0.70 | $-1.49 | $-2.05 | $-2.41 | $-1.07 | $-2.36 | — |
| Operating cash flow | -$39.9M | -$60.5M | -$81.2M | -$94.5M | -$57.1M | -$33.7M | -$21.0M |
| Free cash flow | -$40.0M | -$60.6M | -$81.6M | -$106.1M | -$65.0M | -$34.4M | -$21.4M |
| Cash & equivalents | $54.2M | $57.4M | $125.6M | $47.4M | $92.3M | $157.9M | $7.0M |
| Total assets | $91.0M | $91.0M | $159.6M | $205.3M | $298.6M | $349.0M | $45.0M |
| Total liabilities | $8.6M | $11.4M | $14.9M | $29.2M | $26.8M | $39.1M | $30.5M |
| Shareholders' equity | $82.4M | $79.6M | $144.7M | $176.2M | $271.8M | $309.9M | -$34.5M |
Growth · year-over-year · Revenue CAGR -31.7%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue growth | -82.5% | +245.3% | +154.1% | -97.8% | +202.2% | +0.5% | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.